HMPL-523 ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	1
63	Idiopathic thrombocytopenic purpura	1

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,325 /  Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02105129 (ClinicalTrials.gov)	May 2014	19/3/2014	A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523	A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of HMPL-523	Rheumatoid Arthritis (RA)	Drug: HMPL-523;Drug: Placebo	Hutchison Medipharma Limited	NULL	Completed	18 Years	45 Years	Male	118	Phase 1	Australia

63. Idiopathic thrombocytopenic purpura

---

Clinical trials : 363 /  Drugs : 212 - (DrugBank : 43) / Drug target genes : 47 - Drug target pathways : 138

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05029635 (ClinicalTrials.gov)	October 1, 2021	8/8/2021	Phase III Study on HMPL-523 for Treatment of ITP	A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-523 in Treatment of Primary Immune Thrombocytopenia (ITP) in Adults	Immune Thrombocytopenia (ITP)	Drug: HMPL-523;Drug: Placebo	Hutchison Medipharma Limited	NULL	Not yet recruiting	18 Years	75 Years	All	177	Phase 3	NULL